Gene Logic Expands International Operations - Establishes Staff in UK and Germany
Forms Gene Logic K.K. to Serve Japanese Market
The Company recently reported that 14 percent and 33 percent of its total revenue for the period ended June 30, 2004 resulted from pharmaceutical and biotechnology companies based in Europe and Asia Pacific, respectively. With nearly 50 percent of its revenue generated from non-U.S. based customers, the Company continues to broaden its international presence to better serve existing customers in their home markets and to expand its worldwide customer base. Gene Logic's customers in Europe include Aventis, Novartis, UCB, Boehringer Ingelheim, GlaxoSmithKline and Solvay, and in Asia Pacific include Daiichi, Fujisawa, Mitsubishi, Sankyo, Sumitomo, and Takeda.
Mark D. Gessler, chairman and CEO, Gene Logic, commented, "In establishing international 'customer-facing' staff and infrastructure, Gene Logic will be better able to provide local service to customers in the global marketplace. 'To be global and act local' requires us to be ready to respond to customer needs and offer solutions rapidly and effectively. These initiatives, in combination with our recent establishment of a new research team in Cambridge, Massachusetts, continue our strategy of broadening our services offered and companies served to become the service partner of choice for pharmaceutical and biotechnology companies worldwide."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.